Table 2.

Metabolic biomarkers in predicting MAFLD.

Metabolite	AUC	T-tests	Total (n = 75)	MAFLD (n = 38)	Controls (n = 37)	P-value
Glycyl tyrosine, median (IQR)	0.802	0.063	0.274 (0.212–0.325)	0.216 (0.197–0.274)	0.323 (0.272–0.358)	<0.001
LPC (18:2/0:0), median (IQR)	0.774	2.149	1.953 (0.983–3.261)	1.033 (0.364–1.597)	3.262 (2.613–4.028)	<0.001
LPC (22:6), median (IQR)	0.745	1.492	1.716 (0.972–3.061)	1.039 (0.596–1.47)	2.809 (1.669–3.432)	<0.001
Cer (d18:0/23:0), median (IQR)	0.775	1.197	1.769 (1.382–2.66)	1.323 (1.012–1.769)	2.183 (1.648–3.462)	0.003

AUC area under the Receiver Operating Curve, Cer ceramide, IQR interquartile range, LPC lysophosphatidylcholine, MAFLD Metabolic-dysfunction-associated fatty liver disease.